Denis Talbot

I specialise in thoracic oncology, neuroendocrine tumours and early phase clinical trials. I have published extensively on clinical development of agents targeting cell cycle regulatory proteins, growth factors, DNA repair, macrophage activation and apoptosis, underpinned by translational research focused on proof of concept studies (H Index 52). My publications also reflect my active interest in research ethics, physician/patient communication skills and development of objective assessment tools for evaluating clinical skills. 

Professor Talbot trained in medicine at the University of Cambridge and completed a PhD in Biochemistry at the Institute of Cancer Research, London. He specialises in thoracic oncology, neuroendocrine tumours and early phase clinical trials. He has published extensively on clinical development of agents targeting cell cycle regulatory proteins, growth factors, DNA repair, macrophage activation and apoptosis, underpinned by translational research focused on proof of concept studies (H Index 52). Denis’ publications also reflect his active interest in research ethics, physician/patient communication skills and development of objective assessment tools for evaluating clinical skills. Award of the European ENETS Centre of Excellence status to the Oxford Neuroendocrine Tumour Centre was achieved under his leadership.

He is a member of the British Thoracic Oncology Group Steering Committee, Lung Cancer Clinical Expert Group (CEG), NCRI Neuroendocrine Tumour CEG, Cancer Chemotherapy Information Group for NHS England (National Clinical Lead for SACT), UK Lung Cancer Coalition and ASCO Clinical Guidelines Advisory Groups. Denis is past Chairman of the Specialist Advisory Committee for Medical Oncology and Central Oxford Research Ethics Committees. He has served on the ASCO Faculty, Leukaemia and Lymphoma Research Fund Scientific and Medical Advisory Panels, Cancer Research UK Clinician Scientist Advisory Board and New Agents Committees. He chairs Safety and Data Monitoring Committees for international cancer trials.